


# Encore's Core Product Suite: Moving Rapidly from Source to Value

Encore's tools, coupled with our consultants and methodologies, accelerate your ability to get trusted, transparent data out of your source systems—data you can then use to analyze and improve performance.



## Core Product Descriptions

### eMeasures Data Tool and Knowledge Base


Guides EHR implementation and remediation to get the right data, standards, content, and workflow. Supports customized measures development.

### Value Set Management

Includes lists of specific values (terms and their codes) derived from single or multiple standard vocabularies (SNOMED, ICD-10, ICD-9, RxNorm, LOINC, etc.) used to define clinical concepts (e.g., patients with diabetes, clinical visit, reportable diseases) in eMeasures and required for population analysis. Sourced from regulatory and standards organizations.

### End User eMeasures Specification Editing Tool

Allows analysts to leverage the eMeasures knowledge base to edit and add. Provides simple way to define complex rules for calculating eMeasures using the built-in rule editor. Drives presentation in CoreIQ.



### Smart, Skinny Analytics Engine

Performs in-situ data derivation and measure calculations. Employs metadata from CoreGPS to derive intermediate and complex information from sourced data. Stores these derived elements and logical assertions alongside the detailed source evidence to enable detailed drill-downs, analysis, and reporting. Integrates measure results back into the CoreIQ to enable multi-level analysis and advanced ad-hoc reporting.

## Tools for Accelerating Value through Faster eMeasures Creation

**Value Set Main**

Source Org: <<All>> Program Release: <<All>> **ACE Inhibitor or ARB** Not Posted/Active  
 Taxonomy: <<All>> Steward: <<All>> **OID: 2.16.840.1.113883.3.526.02.39** Version: Dec 2011

Name	Source Org	Taxonomy	Version
ACE Inhibitor or ARB	NQF	RxNorm	Dec 2011
ACE Inhibitors	NQF	RxNorm	Dec 2011
Activation of Emergency Medical System Education	NLM VSAC	SNOMED	Feb 2013
Activation of Emergency Medical System Education	NLM VSAC	SNOMED	New Version
Active Labor	NLM VSAC	SNOMED	Feb 2013
Acute Myocardial Infarction	NQF	ICD-9	Dec 2011
Acute Myocardial Infarction	NQF	ICD-10	Dec 2011
Acute Myocardial Infarction	NQF	SNOMED	Dec 2011
Acute Renal Failure	NQF	SNOMED	Dec 2011
Acute Renal Failure	NQF	ICD-10	Dec 2011
Acute Renal Failure	NQF	ICD-9	Dec 2011

**Value Set Version Terms**

Value	Description	Taxonomy
858621	Enalapril Maleate 5 MG / Felodipine 5 MG Extended Release Tablet	RxNorm
898342	Amlodipine 10 MG / Benazepril hydrochloride 20 MG Oral Capsule	RxNorm
858813	Enalapril Maleate 5 MG Oral Tablet	RxNorm
311353	Lisinopril 2.5 MG Oral Tablet	RxNorm
191438	Captopril 50 MG / Hydrochlorothiazide 15 MG Oral Tablet	RxNorm
898290	Amlodipine 2.5 MG / Benazepril hydrochloride 10 MG Oral Capsule	RxNorm

### CoreGPS®

- Ensures data quality at the source
- Reduces data analysis and source-to-target mapping by 50% or more
- Includes 350+ eMeasures including +1300 value sets mapped to 110,000 data elements

**CoreAUTHOR™**

[Acct Name] Published Measure Specification [3] [Acct Name] Posted Measure Specifications (vte-3.xml)

CHI 1.0 (08/01/2013 3:45 PM)  
 CHI 2.0 (09/14/2013 8:15 PM)  
 CHI 2.1 Measures (10/30/2013 10:30 AM)

Name	Schema	Date Modified
ED-1	1.06	10/30/2013 10:25 AM
ED-2	1.06	10/30/2013 10:25 AM
EH-CoreSet-1A	1.06	10/30/2013 10:25 AM
EH-CoreSet-2	1.06	10/30/2013 10:25 AM
EH-CoreSet-3	1.06	10/30/2013 10:25 AM
EH-CoreSet-4	1.06	10/30/2013 10:25 AM
VTE-3	1.06	10/30/2013 10:25 AM

**VTE 3 - Venous Thromboembolism Patients with Anticoagulation Overlap Therapy**

This measure assesses the number of patients diagnosed with confirmed VTE who received an overlap of parenteral (intravenous [IV] or subcutaneous [subcu]) anticoagulation and warfarin therapy. For patients who received less than five days of overlap therapy, they should be discharged on both medications or have a reason for discontinuation of overlap therapy. Overlap therapy should be administered for at least five days with an international normalized ratio (INR) greater than or equal to 2 prior to discontinuation of the parenteral anticoagulation therapy; discharged on both medications or have a reason for discontinuation of overlap therapy.

- Initial Population (VTE-3-P)**  
Patients with a diagnosis code for venous thromboembolism (VTE), a patient age greater than or equal to 18 years, and a length of stay less than or equal to 120 days.
- Denominator (VTE-3-D)**  
Patients with confirmed VTE who received warfarin.
- Numerator (VTE-3-N1)**  
Patients who received overlap therapy (warfarin and parenteral anticoagulation):
  - Five or more days, with an INR greater than or equal to 2 prior to discontinuation of parenteral therapy, or
  - Five or more days, with an INR less than 2 and discharged on overlap therapy, or
  - Less than five days and discharged on overlap therapy, or
  - With documentation of reason for discontinuation of overlap therapy, or
  - With documentation of a reason for no overlap therapy

### CoreAUTHOR™

- Provides graphical user interface, allowing non-programmers to add or modify eMeasures, accelerating analysis and dashboard creation
- Automates the manual processes, reducing chance for human error

**coreIQ**

Network: Ncare  
 Facility Type: Clinic, Hospital  
 Facility: Marshall, Memorial, Southside, St Lukes, St Marys

**Heart Failure Metrics - Memorial**

Pneumococcal Vaccination  
 Influenza Vaccination  
 Assistance with Tobacco cessation  
 Assessment of Tobacco use  
 Readmission Rate (30 Day)  
 Post-Discharge Appointment for Heart F  
 Left Ventricular Ejection Fraction (LVEF)  
 Beta-Blocker Therapy for Left Ventricula  
 Angiotensin-Converting Enzyme (ACE) I  
 Mortality

**Heart Failure by Age**

Age Group	Percentage
45-64	26.0%
65-74	24.0%
75-84	30.0%
85+	20.0%

**Post-Discharge Appointment for Heart Failure Patients**

Performance Measure Goal

**Performance by Provider**

Provider	Performance
Attending MI	~100
Joseph Dvack	~80
Donna Chang	~60
Susan Michko	~50
James Swains	~40
Angela Harper	~30
Jeffery Polern	~20
Mary McCall	~10
David Owen	~5

### CoreIQ™

- Delivers dashboards for clinical and business owners
- Provides drill-down capabilities for root-cause analysis to drive corrective action